Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation and tumour angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (D...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, A, Hendlisz, A, Gil, T, Bartholomeus, S, Mano, M, de Valeriola, D, Strumberg, D, Brendel, E, Haase, C G, Schwartz, B, Piccart, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361774/
https://www.ncbi.nlm.nih.gov/pubmed/15870716
http://dx.doi.org/10.1038/sj.bjc.6602584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361774/
https://www.ncbi.nlm.nih.gov/pubmed/15870716
http://dx.doi.org/10.1038/sj.bjc.6602584

Ejemplares similares